These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11119921)

  • 1. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
    Tsang WK; Tong KL; Yeung S; Lee W; Chan HW
    Transplant Proc; 2000 Nov; 32(7):1755-6. PubMed ID: 11119921
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
    Suhail SM; Vathsala A; Lou HX; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 5. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Türk H; Böhler T; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):2229. PubMed ID: 9723451
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
    Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
    [No Abstract]   [Full Text] [Related]  

  • 7. Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients.
    Smak Gregoor PJ; Hesse CJ; van Gelder T; van der Mast BJ; IJzermans JN; van Besouw NM; Weimar W
    Transplant Proc; 1998 Jun; 30(4):1192-3. PubMed ID: 9636482
    [No Abstract]   [Full Text] [Related]  

  • 8. Indications for mycofenolate mofetil therapy after liver transplantation.
    Platz KP; Mueller AR; Neuhaus P
    Transplant Proc; 1997 Nov; 29(7):2880-1. PubMed ID: 9365601
    [No Abstract]   [Full Text] [Related]  

  • 9. Mycophenolate mofetil-induced ischemic colitis.
    Kim HC; Park SB
    Transplant Proc; 2000 Nov; 32(7):1896-7. PubMed ID: 11119990
    [No Abstract]   [Full Text] [Related]  

  • 10. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of various immunosuppressive regimes in second renal transplants.
    Toronyi E; Remport A; Járay J; Máthé Z; Borka P; Perner F
    Transplant Proc; 2001 May; 33(3):2315-6. PubMed ID: 11377543
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil improves long-term graft survival following renal transplantation in patients experiencing delayed graft function. International Mycophenolate Mofetil Renal Study Groups.
    Cho S; Hodge E; Navarro M
    Transplant Proc; 1999; 31(1-2):322-3. PubMed ID: 10083126
    [No Abstract]   [Full Text] [Related]  

  • 13. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.
    Carl S; Dörsam J; Mandelbaum A; Staehler G; Wiesel M
    Transplant Proc; 1998 Jun; 30(4):1236-7. PubMed ID: 9636502
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Morgera S; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Jun; 30(4):1190-1. PubMed ID: 9636481
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic study of mycophenolate mofetil in Asian renal transplant recipients.
    Yeung S; Tong KL; Tsang WK; Chan HW; Chan AY
    Transplant Proc; 2000 Nov; 32(7):1753-4. PubMed ID: 11119920
    [No Abstract]   [Full Text] [Related]  

  • 16. Omission of azathioprine and mycophenolate mofetil in immunosuppressive regimen in kidney transplantation.
    Taheri M; Pourmand G; Mehrsai AR; Mansoori D
    Transplant Proc; 2003 Nov; 35(7):2752-3. PubMed ID: 14612105
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K; Kim SI; Moon JI; Kim YS; Kim MS
    Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolerability of mycophenolate mofetil in organ transplant recipients.
    Schweizer RT; Meisterling LD
    Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.
    Song Y; Xue W; Tian P; Ding X; Pan X; Yan H; Hou J; Feng X; Xiang H; Tian X; Qin G; Fan X
    Eur J Clin Pharmacol; 2011 Jun; 67(6):553-62. PubMed ID: 21279337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.